Home

Korro Bio, Inc. - Common Stock (KRRO)

6.0700
-0.4300 (-6.62%)
NASDAQ · Last Trade: Nov 14th, 7:38 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close6.500
Open5.770
Bid6.040
Ask6.070
Day's Range5.700 - 6.560
52 Week Range5.700 - 70.49
Volume2,063,324
Market Cap221.68M
PE Ratio (TTM)-0.6451
EPS (TTM)-9.4
Dividend & YieldN/A (N/A)
1 Month Average Volume706,304

Chart

About Korro Bio, Inc. - Common Stock (KRRO)

Korro Bio, Inc. is a biotechnology company focused on advancing RNA-targeted therapies to treat various genetic diseases. The company develops innovative solutions leveraging its proprietary technologies aimed at delivering precise and effective treatments through the modulation of RNA. Korro Bio is dedicated to addressing unmet medical needs by harnessing the potential of RNA biology and transforming therapeutic approaches for patients suffering from serious health conditions. Through its research and development efforts, the company strives to pioneer advances in the field of precision medicine. Read More

News & Press Releases

12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · November 13, 2025
Keep an eye on the top gainers and losers in Thursday's session.chartmill.com
Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · November 13, 2025
Korro Bio Early Trial Results Fall Short; Stock Hits New Lowbenzinga.com
Korro Bio shares drop after KRRO-110 trial in AATD misses protein goals; company cuts 34% of staff and shifts focus to liver-targeted programs.
Via Benzinga · November 13, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · November 13, 2025
Korro Bio Stock Crashes Over 75% After-Hours On Drug Failure, Downgrades And Layoffs — Yet Retail Flags ‘Buy-The-Fear’ Setupstocktwits.com
Via Stocktwits · November 12, 2025
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Resultsbenzinga.com
Via Benzinga · November 13, 2025
Which stocks are gapping on Thursday?chartmill.com
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill · November 13, 2025
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Resultsbenzinga.com
Via Benzinga · November 13, 2025
Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editinginvestors.com
Korro Bio stock plummeted Thursday after its RNA-editing drug failed in patients with a rare lung and liver disease.
Via Investor's Business Daily · November 13, 2025
Stay updated with the stocks that are on the move in today's pre-market session.chartmill.com
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · November 13, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 13, 2025
Why Cisco Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · November 13, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · October 20, 2025
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scoresbenzinga.com
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores.
Via Benzinga · September 12, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · September 3, 2025
12 Health Care Stocks Moving In Tuesday's After-Market Sessionbenzinga.com
Via Benzinga · May 27, 2025
Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursdaybenzinga.com
Via Benzinga · May 8, 2025
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesdaybenzinga.com
Via Benzinga · April 16, 2025
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors
Industry veterans John Maraganore, Ph.D., and Rachel Meyers, Ph.D., to provide strategic guidance on the company’s RNA Actuating platform to develop a new class of RNA medicines that upregulate protein coding genes
By CAMP4 Therapeutics · Via GlobeNewswire · December 10, 2024
This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga.com
Via Benzinga · November 18, 2024
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.investors.com
Korro Bio is lagging Wave Life Sciences. But an analyst says it could ultimately be the leader.
Via Investor's Business Daily · October 21, 2024
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · October 16, 2024
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · October 16, 2024
3 Stocks That Could Rise on European Bank Interest Rate Cuts
The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit.
Via MarketBeat · September 22, 2024
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocksfool.com
This strategic play will take time to pay off, but it could keep growth going.
Via The Motley Fool · September 19, 2024